Immunohistochemical and Clinical Characterization of the Basal-like Subtype of Invasive Breast Carcinoma Homepage  
Treeview CaseXplorer  
Figures from the paper  
Stanford Tissue Microarray Consortium Web Portal  


Figure 1. Gene expression patterns in basal-like tumors and their correlation with immunohistochemistry. A) The 115 patient/tumor sample dendrogram was taken from the hierarchical clustering analysis presented in Sorlie et al. 2003 (2); the tumors were grouped using the breast "intrinsic" gene list based upon 50 paired samples. The BBC are identified in red. The gene expression data for ER, HER2, c-KIT, CK5 and HER1 are shown with red squares representing the highest average expression, black representing average gene expression and green r epresenting the lowest below average. B) 21 BBC identified by gene expression profiling were tested and scored by IHC for CK5/6, HER1, c-KIT, ER and HER2 (0 = negative, 1 = weak and/or focal staining, 2 = strong diffuse staining), except for HER2, which was scored using a standard (0-3+) scale. ND = not determined. C) Representative immunostaining results for 4 basal-like tumors and a normal breast sample for CK5/6 and HER1. Warning: Large file 17MB

Figure 2. Figure 2. Kaplan-Meier survival curves based upon basal cytokeratin and HER1 staining. A)Kaplan-Meier disease-specific survival (DSS) curve for 829 tumours assessed for cytokeratin 5/6 and cytokeratin 17. B)Kaplan-Meier disease-specific survival (DSS) curve for 472 lymph node positive breast cancers assessed for cytokeratin 5/6 and cytokeratin 17. C)Kaplan-Meier disease-specific survival (DSS) curve for 210 lymph node negative breastcancers assessed for cytokeratin 5/6 and cytokeratin 17. D)Kaplan Meier disease-specific survival (DSS) curve in 609 breast cancers assessed for HER1 immunostaining.

Figure 3. Hierarchical cluster analysis of breast carcinoma tissue microarray immunostaining results. The six markers evaluated in this study (ER, HER1, HER2, c-KIT, CK5/6 and CK17) were scored and used in a clustering analysis where each row represents a different tumor, and each column represents a different IHC stain. The analysis shows that the basal-like markers stained similar cases, as indicated by the very short dendrogram branches linking these markers.
Figure 4. Kaplan Meier disease specific survival (DDS) analysis of breast carcinoma subtypes defined by ER, HER2, CK5/6 and HER1 immunohistochemistry. Group B (the basal-like subtype) is defined as negative for ER, negative for HER2 and positive for HER1 and/or CK5/6. Group E (the luminal subtype) are positive for ER and negative for HER2. Group H (clinically HER2 3+) are positive for HER2.

[ Home | CaseXplorer | Figures | WebPortal | Authors ]